logo
  

EverBank Financial Q4 Profit Rises - Quick Facts

EverBank Financial Corp. (EVER) reported that its fourth-quarter net income available to common shareholders rose to $35.49 million or $0.28 per share from $15.92 million or $0.13 per share in the same period last year.

Excluding the impact of $2.1 million in non-recurring regulatory and other expenses, net of tax, adjusted net income for the quarter would have been $37.62 million, or $0.30 per share. This compares to adjusted net income of $29.69 million or $0.24 per share in the prior-year quarter.

On average, 11 analysts polled by Thomson Reuters expected the company to earn $0.30 per share for the quarter. Analysts' estimates typically exclude special items.

Net interest income grew to $147.44 million from $135.04 million in the year-ago quarter, while total non-interest income declined to $75.17 million from $95.71 million last year. Analysts estimated revenues of $228.97 million.

On January 22, 2015, the company's board of directors declared a quarterly cash dividend of $0.04 per common share, payable on February 20, 2015, to stockholders of record as of February 11, 2015.

Also on January 22, 2015, the board declared a quarterly cash dividend of $421.875, payable on April 6, 2015, for each share of 6.75 percent Series A Non-Cumulative Perpetual Preferred Stock held as of March 20, 2015.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
French drug major Sanofi reported Thursday weak profit in its first quarter, despite higher net sales. The company also maintained its fiscal 2024 outlook. Sanofi shares were gaining around 4 percent in Paris trading as well as in pre-market activity on the Nasdaq. While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates.

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
Follow RTT